Hong Kong Looks To EU For New Advanced Therapy Rules
Executive Summary
Hong Kong is consulting on proposals to include advanced therapies in its regulatory framework for pharmaceuticals.
You may also be interested in...
Scrutiny In Store For Hong Kong’s First Advanced Therapy Rules
Requirements for advanced therapies in Hong Kong are being modeled on the EU regulatory regime.
Scrutiny In Store For Hong Kong’s First Advanced Therapy Rules
Requirements for advanced therapies in Hong Kong are being modeled on the EU regulatory regime.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.